Sichuan Kelun-Biotech Biopharmaceutical's (HKG:6990) new drug application (NDA) for trastuzumab botidotin was accepted by China's National Medical Products Administration, a Tuesday bourse filing said.
The product is indicated for the treatment of adult patients with HER2 positive unresectable or metastatic breast cancer who have received at least one prior anti-HER2 therapy, according to the biopharmaceutical company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.